FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/02/2026
Voltar para busca
Dado oficial do USPTO
ABOGENBIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
20/02/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
01/11/2021
Data de registro
15/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/07/2025
Última transação
20/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
CN
Examinador
HARMON, RAYMOND E
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "ABOGENBIO".
Titulares e representantes
Titulares
Suzhou Abogen Biosciences Co., Ltd.
Representantes
THOMAS HOXIE HOXIE & ASSOCIATES LLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment or prevention of cancerinfectious diseases; chemico-pharmaceutical preparations for the treatment or prevention of cancer and infectious diseases; drugs being pharmaceutical preparations for medical purposes for the treatment or prevention of cancer and infectious diseases; biological preparations for the treatment or prevention of cancer and infectious diseases for medical purposes; medicines for the treatment or prevention of cancer and infectious diseases for human purposes; chemical preparations for medical purposesfor the treatment or prevention of cancer and infectious diseases; crude drug being homeopathic pharmaceuticals for the treatment of infectious viral diseases;lipid particle for nucleotide drug delivery purpose for the treatment or prevention of cancer and infectious diseases; and biochemical medicines for the treatment or prevention of cancer and infectious diseases; dietetic substances being foods and beverages adapted for medical use for the treatment or prevention of cancer and infectious diseases
Classe 42
Technological research in the field of medical researchspecifically for the treatment or prevention of cancer and infectious diseases; quality controlspecifically for products for the treatment or prevention of cancer and infectious disease; product quality testingspecifically for products for the treatment or prevention of cancer and infectious diseases; cancer research for medical purposes; pharmaceutical drug development servicesspecifically for pharmaceutical drugs for the treatment or prevention of cancer and infectious diseases; pharmaceutical product evaluationdrug evaluationspecifically for the treatment or prevention of cancer and infectious diseases; pharmaceutical research servicesspecifically for products for the treatment or prevention of cancer and infectious diseases; medical researchspecifically for the treatment or prevention of cancer and infectious diseases; development of pharmaceutical preparations and pharmaceuticalsspecifically for products for the treatment or prevention of cancer and infectious diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/02/2026
FIMP
FINAL DISPOSITION PROCESSED
05/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
15/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
15/07/2025
TMBN
TTAB RELEASE CASE TO TRADEMARKS
24/06/2025
OP.T
OPPOSITION TERMINATED NO. 999999
24/06/2025
OP.D
OPPOSITION DISMISSED NO. 999999
24/06/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/05/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
31/05/2023
RFNT
REFUSAL PROCESSED BY IB
19/04/2023
OP.I
OPPOSITION INSTITUTED NO. 999999
27/03/2023
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
22/03/2023
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
22/03/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
15/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/11/2022
PUBO
PUBLISHED FOR OPPOSITION
22/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/10/2022
RFNT
REFUSAL PROCESSED BY IB
12/09/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/08/2022
RFRR
REFUSAL PROCESSED BY MPU
23/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/08/2022
CNRT
NON-FINAL ACTION WRITTEN
16/08/2022
DOCK
ASSIGNED TO EXAMINER
10/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
07/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/01/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ABOGENBIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.